Montai Health welcomes Dr. Michael Severino and Andreas Fibig to its Board of Directors

– USA, MA –  Montai Health, a company unlocking the power of nature with digital technologies to treat and preempt chronic disease, today announced the appointments of Dr. Michael Severino (M.D.) and Andreas Fibig to its Board of Directors, bringing decades of drug development and commercialization leadership experience to the Board.

“I’m thrilled to welcome Michael and Andreas to the board as we seize the unprecedented opportunity to address the global burden of chronic disease. They are proven leaders with experience guiding companies through transformational growth and bring important and unique perspectives to Montai,” said Margo Georgiadis, co-founder, and CEO of Montai Health and CEO-Partner, Flagship Pioneering. “Their exceptional track records leading global pharmaceutical companies, including research and development in inflammation and autoimmune disease, the commercialization of impactful medicines, and strategic partnerships, will enhance our success as we rapidly advance our platform and pipeline.”

About Dr. Michael SeverinoMichael Severino,

M.D. brings more than two decades of experience in biopharmaceutical leadership and has made significant contributions to the research, development, registration, and commercialization of more than a dozen approved therapies. Dr. Severino is currently the CEO of Tessera Therapeutics. In prior roles at AbbVie, including EVP of Research and Development, CSO, and most recently, Vice-Chairman and President, Dr. Severino led efforts to build a strong pipeline and advance promising therapies for patients in multiple disease areas. While at AbbVie, he identified vital research collaboration opportunities in hematologic oncology, immunology, and neuroscience. Previously, Dr. Severino held several senior leadership roles at Amgen, leading to his appointment as SVP and Corporate CMO, overseeing the company’s global clinical development efforts.

About Andreas Fibig

Andreas Fibig is the former CEO and Chairman of International Flavors & Fragrances and the former President of Bayer. He brings nearly four decades of experience leveraging the intersection of natural products and pharmaceutical medicines to create significant commercial opportunities. At IFF, an industry leader in food ingredients, beverage, scent, health, and biosciences, Mr. Fibig led the company through a transformational period, overseeing the integration of DuPont Nutrition & Biosciences into the company, spearheading the organization’s sustainability efforts, and driving strong sales growth. Previously, he served as President and Chairman of the Board of Management for Bayer Health Care Pharmaceuticals, where he was responsible for Bayer’s global healthcare and pharmaceutical business. During his tenure, the company launched multiple new medicines to help patients with serious unmet medical needs while enhancing business development and marketing capabilities and accelerating growth to industry-leading rates.

Mr. Fibig currently serves on the Board of Directors for Novo Nordisk and previously served on the Board of Directors for Bunge Limited.

About Montai Health

Montai Health is unlocking the power of nature with its pioneering AI-powered CONECTA platform to develop Anthromolecule medicines that will treat and preempt chronic diseases to improve health outcomes for the 2 billion people worldwide living with these diseases. Anthromolecule chemistry has co-evolved with humans through the long-term regular consumption of foods, herbs, and traditional medicines. It offers a privileged starting point for developing breakthrough small-molecule medicines to address chronic diseases. Montai’s CONECTA platform is powered by hyper-efficient, generalizable ML and the aggregation of Anthromolecule chemistry at industry first scale to predictably discover precision-matched, human-qualified chemistry that potently and safely engages validated biological pathways. Montai is rapidly advancing a pipeline of first-in-class or best-in-class small-molecule assets against multiple powerful, validated biological pathways in inflammation and autoimmune. Montai was founded in Flagship Labs in 2019.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.